Supernus to Host Second Quarter 2021 Financial Results globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Operator
Good afternoon and welcome to Supernus Pharmaceuticals First Quarter 2021 Financial Results Conference Call. [Operator Instructions] I would now like to turn the conference over to Peter Vozzo of Westwicke, Investor Relations representative for Supernus Pharmaceuticals. You may begin.
Peter Vozzo
Investor Relations Representative, Supernus Pharmaceuticals
Thank you, here again. Good afternoon everyone and thank you for joining us today for Supernus Pharmaceuticals First Quarter 2021 Financial Results Conference Call. Today after the close of the market, the company issued a press release announcing these results. On the call with me today are Supernus Chief Executive Officer, Jack Khattar; and Jim Kelly, Chief Financial Officer. Today s call is being made available via the Investor Relations section of the company s website at ir.supernus.com. Following remarks by management, we will open the call to questions.
Supernus to Host First Quarter 2021 Financial Results Conference Call forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Published: Apr 20, 2021
Pittsburgh, April 20, 2021 (GLOBE NEWSWIRE) Cognition Therapeutics Inc., a clinical stage neuroscience company developing drugs that treat degenerative disorders by regulating cellular damage response pathways, announced that the board of directors has elected Jack A. Khattar chairman of the board. Mr. Khattar, the founder and CEO of Supernus Pharmaceuticals, was appointed in 2020 to serve as a member of the Cognition board of directors. He replaces former chairman, Robert J. Gailus, who has retired from the board of directors.
“Even in the short time that he has been a member of the board, Jack’s contributions have been significant. As chairman, we will draw more heavily on Jack’s expertise as we pursue a growing repertoire of indications and clinical plans,” stated President and CEO Lisa Ricciardi, “Bob’s retirement from the board comes after a remarkable tenure. He was one of Cognition’s earliest angel investors and continued to pro